Evidence method
Level · gp.fundamentals.debt_to_revenue
23.20% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Sep 30, 2026
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration
State dimensions
Filing0000105770-26-000121General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.47% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
21.67% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
8.69% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
53.14% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
39.73% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
30.58% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.09% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
0.49% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 23.26%
- Current
- 23.20%
- Delta
- -0.06%
- Previous
- 4.95%
- Current
- 4.47%
- Delta
- -0.48%
- Previous
- 14.22%
- Current
- 21.67%
- Delta
- 7.45%
- Previous
- 13.80%
- Current
- 8.69%
- Delta
- -5.12%
- Previous
- 51.29%
- Current
- 53.14%
- Delta
- 1.85%
- Previous
- 37.74%
- Current
- 39.73%
- Delta
- 1.99%
- Previous
- 20.53%
- Current
- 30.58%
- Delta
- 10.05%
- Previous
- 2.26%
- Current
- 2.09%
- Delta
- -0.17%
- Previous
- 1.25%
- Current
- 0.49%
- Delta
- -0.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
- Similarity
- 78%
- Compared
- 9 dimensions
- Coverage
- 100%
- Similarity
- 75%
- Compared
- 8 dimensions
- Coverage
- 89%
- Similarity
- 73%
- Compared
- 9 dimensions
- Coverage
- 100%
- Similarity
- 73%
- Compared
- 9 dimensions
- Coverage
- 100%
- Similarity
- 68%
- Compared
- 7 dimensions
- Coverage
- 78%
Research Graph
Related governed research
Analogous To · WST state analogue 5 →Analogous To · WST state analogue 2 →Analogous To · WST state analogue 3 →Analogous To · WST state analogue 1 →Compared To · Surgical & Medical Instruments & Apparatus peers →Analogous To · WST state analogue 4 →Derived From · WST Company Quality Vector →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · WST CAPEX_INTENSITY_DECREASED →Transitioned To · WST CASH_GENERATION_INCREASED →Transitioned To · WST GROWTH_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.